Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3- yl)benzylamine with elucidation of bioactive conformation: Discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5101-5113

  Kolhatkar, Rohit ^a   Cook, Charles D ^b   Ghorai, Sujit K ^a   Deschamps, Jeffrey ^c   Beardsley, Patrick M ^b   Reith, Maarten E A ^d   Dutta, Aloke K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NAVAL RESEARCH LABORATORY   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 BENZHYDRYL 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 (3,4 DICHLOROBENZYL) 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 (4 ETHOXYBENZYL) 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 (4 FLUOROBENZYL) 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 (4 METHOXYBENZYL) 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 (4 NITROBENZYL) 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 [2 (4 FLUOROPHENYL)ETHYL] 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 METHYL 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 NAPHTHALEN 1 YLMETHYL 1,4 DIAZABICYCLO[3.3.1]NONANE; 8 BENZHYDRYL 4 NAPHTHALEN 2 YLMETHYL 1,4 DIAZABICYCLO[3.3.1]NONANE; BENZHYDRYL DERIVATIVE; CIS(6 BENZHYDRYLPIPERIDIN 3 YL)BENZYLAMINE; CITALOPRAM; DOPAMINE TRANSPORTER; NISOXETINE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; COCAINE DEPENDENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG MECHANISM; ENANTIOMER; IN VIVO STUDY; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZHYDRYL COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; CRYSTALLOGRAPHY, X-RAY; DISCRIMINATION LEARNING; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PIPERIDINES; RADIOLIGAND ASSAY; RATS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS;

EID: 4744375699     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049796t     Document Type: Article

References (35)

1. Ritz, M. C.; Cone, E. J.; Kuhar, M. J. Cocaine inhibition of ligand binding at dopamine, norpinephrine and serotonin transporters: A structure-activity study. Life Sci. 1990, 46, 635-645.
2. Ritz, M. C.; Lamb, R. J.; Goldberg, R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-adminstration of cocaine. Science. 1987, 237, 1219-1223.
3. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends. Neurosci. 1991, 14, 299-302.
4. Witkin, J. M.; Nichols, D. E.; Terry, P.; Katz, J. L. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J. Pharmacol. Exp. Ther. 1991, 257, 706-713.
5. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379, 606-612.
6. Spealman, R. D.; Madras, B. K.; Bergman, J. 1989. Effects of Cocaine and Related Drugs in Nonhuman Primates. II. Stimulant Effects on Schedule-Controlled Behav. Pharmacol. Exp. Ther. 1989, 251, 142-149.
7. Carboni, E.; Spielewoy, C.; Vacca, C.; Nosten-Bertrand M.; Giros, B.; Di Chiara, G. Cocaine and Amphetamine Increase Extracellular Dopamine in the Nucleus Accumbens of Mice Lacking the Dopamine Transporter Gene. J. Neurosci. 2001, 21, RC141.
8. Walsh, S. L.; Cunningham, K. A. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology 1997, 130, 41-58.
9. Carroll, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for Treatment of Cocaine Abuse: Preclinical Aspects. J. Med. Chem. 1999, 42, 2721-2736.
10. Carrol, F. I.; Lewin, A. H.; Mascarella, S. W. Dopamine transporter uptake blockers: Structure activity relationships. In neurotransmitter transporters: Structure and function, 2nd ed.; Reith, M. E. A., Eds.; Human Press: Totowa, NJ, 2002, pp 381-432.
11. Singh, S. Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem. Rev. 2000, 100, 925-1024.
12. Dutta, A, K.; Zhang, S.; Kolhatkar, R.; Reith, M. E. A. Dopamine transporter as target for drug development of cocaine dependence medications. Eu. J. Pharmacol. 2003, 479, 93-106.
13. Dutta, A. K.; Xu, C.; Reith, M. E. A. Structure-Activity Relationship Studies of Novel 4-[2-[Bis(4-fluorophenyl)methoxy]- ethyl]-1-(3-phenylpropyl) piperidine Analogues: Synthesis and Biological Evaluation at the Dopamine and Serotonin Transporter Sites. J. Med. Chem. 1996, 39, 749-756.
14. Dutta, A. K; Coffey, L. L.; Reith, M. E. A. Highly selective, novel analogues of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the dopamine transporter: Effect of different aromatic substitutions on their affinity and selectivity. J. Med. Chem. 1897, 40, 35-43.
15. Dutta, A. K.; Fei, X.-S.; Beardsley, P.; Newman, J.; Reith, M. E. A. Structure-Activity Relationship Studies of 4-[2-(Diphenylmethoxy)-ethyl]-1- benzylpiperidine Derivatives and their N- analogues: Evaluation of Behavioral Activity of O-and N-Analogues and their Binding to Monoamine transporters. J. Med. Chem. 2001, 44, 937-948.
16. Dutta, A. K.; Davis, M. C.; Reith, M. E. A. Rational Design and synthesis of novel conformationally constrained 2,5-disubstituted cis- and tras-piperidine derivatives exhibiting differential activity for the dopamine transporter. Bioorg. Med. Lett. 2001, 11, 2337-2340.
17. Kolhatkar, R. B.; Ghorai, S. K.; George, C.; Reith, M. E. A.; Dutta, A K. Interaction of cis-(6-benzhydryl-piperidin-3-yl)- benzyl-amine analogues with monoamine transporters: Structure Activity Relationship study of structurally constrained 3,6- disubstituted piperidine analogues of (2,2-diphenylethyl)-[1- (4- fluorobenzyl)piperidine-4-ylmethyl]amine. J. Med. Chem. 2003, 46, 2205-2215.
18. Zhang, Y.; Rothman, R. B.; Dersch, C. M.; de Costa, B. R.; Jacobson, A. E.; Rice, K. C. Synthesis and transporter binding properties of bridged piperazine analogues of 1-{2-[bis(4-fluorophenyl)methoxy]ethyl}-4-(3- phenylpropyl)piperazine (GBR 12909). J. Med. Chem. 2000, 43, 4840-4849.
19. Bradley, A. L.; Izenwasser, S.; Wade, D.; Cararas, S.; Trudell, M. L. Synthesis of dopamine transporter selective 3-{2-(diarylmethoxyethylidene)}-8- alkylaryl-8-azabicyclo [3.2.1] octanes. Bioorg. Med. Chem. Lett. 2003, 13, 629-632.
20. Bradley, A. L.; Izenwasser, S.; Wade, D.; Klein-Stevens, C.; Zhu, N.; Trudell, M. L. Synthesis and dopamine transporter binding affinities of 3a-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]- octanes. Bioorg. Med. Chem. Lett. 2002, 12, 2387-2390.
21. Velazquez-Campoy A.; Freire, E. Incorporating target heterogeneity in drug design. J. Cell Biochem. Suppl. 2001, 37, 82-88.
22. Paluchowska, M. H.; Mokrosz, M. J.; Bojarski, A.; Wesolowska, A.; Borycz, J.; Charakchieva, S.; Chojnacka-Wojcik, E. On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5HT1a receptor antagonists. J. Med. Chem. 1999, 42, 4952-4960.
23. de Laszlo, S. E.; Glinka, T. W.; Greenlee, W. J.; Ball, R.; Nachbar, R. B.; Prendergast, K. The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists. Bioorg. Med. Chem. Lett. 1996, 6, 923-928.
24. Hruby, V. J. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci. 1982, 31, 189-199.
25. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Dev. Rev. 1997, 23, 3-25.
26. Suomalainen, P.; Johans, C.; Soderlund, T.; Rmnunen, K. J. Surface activity profiling of drugs applied to the prediction of blood-brain berrier permeability. J. Med. Chem. 2004, 47, 1783-1788.
27. Kelder, J.; Grootenhuis, D. J. P.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 10, 1514-1519.
28. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
29. Adams, R.; Bachmann, W. E.; Biatt, A. H.; Fisher, L. F.; Johnson J. R.; Snyder H. K. Organic Reactions; John Wiley & Sons Inc.: New York, 1949; Volume V, Chapter 7, p 301.
30. Tamiz, A. P.; Zhang, J.; Flippen-Anderson, J. L.; Zhang, M.; Johnson, K. M.; Deschaux, O.; Tella, S.; Kozikowski, A. P. Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors. J. Med. Chem. 2000, 43, 1215-1222.
31. Davies, H. M.; Gilliatt, V.; Kuhn, L. A.; Saikali, E.; Ren, P.; Hammond, P. S.; Sexton, T.; Childers, S. R. Synthesis of 2/3- acyl-3β-(substituted naphthyl)-8-azabicyclo[3.2.1]octanes and their binding affinities at dopamine and serotonin transport sites. J. Med. Chem. 2001, 44, 1509-1515.
32. Ghorai S.; Cook C. D.; Davis M.; Venkataraman S.; Beardsley P.; Reith M. E. A.; Dutta A K. High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: Stereospecific interactions in vitro and in vivo. J. Med. Chem. 2003, 46, 1220-1228.
33. (a)Bruker 1999. SMART v5.059. Bruker AXS Inc., Madison, WI.
34. (b) Bruker 2000. SAINT v6.02A. Bruker AXS Inc., Madison, WI.
35. (c) Bruker (2000b). SHELXTL v6.10. Bruker AXS Inc., Madison, WI.